Market Overview:
The global carcinoembryonic antigen assay kit market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth in the market can be attributed to the increasing incidence of cancer, technological advancements in assay kits, and rising demand for early diagnosis of cancer. Based on type, the global carcinoembryonic antigen assay kit market is segmented into chemiluminescence method and microparticle enzyme-linked immunoassay (ELISA). The chemiluminescence method segment is expected to grow at a higher CAGR than the microparticle ELISA segment during the forecast period. This can be attributed to technological advancements in this methodology that have made it more sensitive and specific than other methods. Based on application, the global carcinoembryonic antigen assay kit market is divided into hospital laboratories, pharmacy laboratories, teaching and research institutions, and other applications such as point-of-care testing (POCT) and veterinary diagnostics. The hospital laboratories segment accounted for majority share of the global carcinoembryonic antigen assay kit market in 2017 owing to increasing number of hospitals worldwide coupled with rising demand for early diagnosis of cancer patients.
Product Definition:
The Carcinoembryonic Antigen Assay Kit is a diagnostic assay used to measure the level of carcinoembryonic antigen (CEA) in human serum or plasma. CEA is a glycoprotein found on the surface of some cancer cells. The level of CEA in serum or plasma can be used as an indicator of how advanced a person's cancer is and can help guide treatment decisions.
Chemiluminescence Method:
The chemiluminescence method is a new-age technology that has overcome the drawbacks of other immunoassay techniques. The method provides highly sensitive and accurate results in detecting tumor cells, thereby augmenting the demand for its use in clinical oncology laboratories.
Microparticle enzyme-linked Immunoassay:
A microparticle enzyme-linked immunoassay (MEIA) is a technique that involves the use of small particles, usually latex or microcarriers to carry the enzymes and substrates. The MEIA process takes place in an aqueous solution and utilizes light or electromagnetic radiation for detection.
Application Insights:
The hospital application segment accounted for the largest revenue share in 2017. The increasing prevalence of cancer and the need for rapid diagnosis are factors contributing to the growth of this segment. Carcinoembryonic antigen assay is used as a diagnostic tool in various cancers, including lung, colorectal, breast and prostate cancer.
In addition, it has been found that immunotherapy using carcinoembryonic antigen assay can be used to determine response during treatment with chemotherapy or hormonal therapy alone or in combination with other therapies such as surgery or radiotherapy. This has led to an increase in its adoption by oncology laboratories across the globe.
Pharmacy application is expected to grow at a lucrative rate over the forecast period owing to rising incidences of chronic diseases such as diabetes.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of a large number of players, high investment in R&D, and increasing healthcare expenditure. Moreover, increasing incidence of cancer is also expected to boost CAR-T cell therapies over the forecast period. The U.S.
Asia Pacific region is anticipated to witness lucrative growth during the forecast period owing to growing target population base with increased susceptibility towards infections caused by Carbapenem-resistant Enterobacteriaceae (CRE).
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is the major growth driver for the Carcinoembryonic Antigen Assay Kit market. According to the World Health Organization, in 2012, there were 14 million new cases of cancer and 8.2 million deaths due to cancer worldwide. This number is expected to increase by about 70% over the next two decades. This will create a large demand for Carcinoembryonic Antigen Assay Kits as they are used for early diagnosis and treatment of cancers.
- Rising awareness about early detection: There is an increasing awareness among people about the importance of early detection of cancers. This has led to an increase in demand for Carcinoembryonic Antigen Assay Kits as they help in early diagnosis of cancers.
- Technological advancements: The technological advancements in diagnostic techniques have led to increased use of Carcinoembryonic Antigen Assay Kits for diagnosing various types of cancers at an earlier stage..This is further propelling the growth prospects for this market during the forecast period .
Scope Of The Report
Report Attributes
Report Details
Report Title
Carcinoembryonic Antigen Assay Kit Market Research Report
By Type
Chemiluminescence Method, Microparticle enzyme-linked Immunoassay
By Application
Hospital, Pharmacy, Teaching and Research Institutions, Other
By Companies
Siemens, Abbott Ireland Diagnostics Limited, Roche Diagnostics GmbH, Danaher, Biomatik, RayBiotech, Inc., LifeSpan BioSciences, Biorbyt, OriGene Technologies, Aviva Systems Biology Corporation
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
130
Number of Tables & Figures
91
Customization Available
Yes, the report can be customized as per your need.
Global Carcinoembryonic Antigen Assay Kit Market Report Segments:
The global Carcinoembryonic Antigen Assay Kit market is segmented on the basis of:
Types
Chemiluminescence Method, Microparticle enzyme-linked Immunoassay
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Pharmacy, Teaching and Research Institutions, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Siemens
- Abbott Ireland Diagnostics Limited
- Roche Diagnostics GmbH
- Danaher
- Biomatik
- RayBiotech, Inc.
- LifeSpan BioSciences
- Biorbyt
- OriGene Technologies
- Aviva Systems Biology Corporation
Highlights of The Carcinoembryonic Antigen Assay Kit Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Chemiluminescence Method
- Microparticle enzyme-linked Immunoassay
- By Application:
- Hospital
- Pharmacy
- Teaching and Research Institutions
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Carcinoembryonic Antigen Assay Kit Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
The Carcinoembryonic Antigen Assay Kit is a diagnostic tool used to determine the presence of cancer cells in a sample.
Some of the major players in the carcinoembryonic antigen assay kit market are Siemens, Abbott Ireland Diagnostics Limited, Roche Diagnostics GmbH, Danaher, Biomatik, RayBiotech, Inc., LifeSpan BioSciences, Biorbyt, OriGene Technologies, Aviva Systems Biology Corporation.
The carcinoembryonic antigen assay kit market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Carcinoembryonic Antigen Assay Kit Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Carcinoembryonic Antigen Assay Kit Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Carcinoembryonic Antigen Assay Kit Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Carcinoembryonic Antigen Assay Kit Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Carcinoembryonic Antigen Assay Kit Market Size & Forecast, 2018-2028
4.5.1 Carcinoembryonic Antigen Assay Kit Market Size and Y-o-Y Growth
4.5.2 Carcinoembryonic Antigen Assay Kit Market Absolute $ Opportunity
Chapter 5 Global Carcinoembryonic Antigen Assay Kit Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Carcinoembryonic Antigen Assay Kit Market Size Forecast by Type
5.2.1 Chemiluminescence Method
5.2.2 Microparticle enzyme-linked Immunoassay
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Carcinoembryonic Antigen Assay Kit Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Carcinoembryonic Antigen Assay Kit Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Pharmacy
6.2.3 Teaching and Research Institutions
6.2.4 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Carcinoembryonic Antigen Assay Kit Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Carcinoembryonic Antigen Assay Kit Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Carcinoembryonic Antigen Assay Kit Analysis and Forecast
9.1 Introduction
9.2 North America Carcinoembryonic Antigen Assay Kit Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Carcinoembryonic Antigen Assay Kit Market Size Forecast by Type
9.6.1 Chemiluminescence Method
9.6.2 Microparticle enzyme-linked Immunoassay
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Carcinoembryonic Antigen Assay Kit Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Pharmacy
9.10.3 Teaching and Research Institutions
9.10.4 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Carcinoembryonic Antigen Assay Kit Analysis and Forecast
10.1 Introduction
10.2 Europe Carcinoembryonic Antigen Assay Kit Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Carcinoembryonic Antigen Assay Kit Market Size Forecast by Type
10.6.1 Chemiluminescence Method
10.6.2 Microparticle enzyme-linked Immunoassay
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Carcinoembryonic Antigen Assay Kit Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Pharmacy
10.10.3 Teaching and Research Institutions
10.10.4 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Carcinoembryonic Antigen Assay Kit Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Carcinoembryonic Antigen Assay Kit Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Carcinoembryonic Antigen Assay Kit Market Size Forecast by Type
11.6.1 Chemiluminescence Method
11.6.2 Microparticle enzyme-linked Immunoassay
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Carcinoembryonic Antigen Assay Kit Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Pharmacy
11.10.3 Teaching and Research Institutions
11.10.4 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Carcinoembryonic Antigen Assay Kit Analysis and Forecast
12.1 Introduction
12.2 Latin America Carcinoembryonic Antigen Assay Kit Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Carcinoembryonic Antigen Assay Kit Market Size Forecast by Type
12.6.1 Chemiluminescence Method
12.6.2 Microparticle enzyme-linked Immunoassay
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Carcinoembryonic Antigen Assay Kit Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Pharmacy
12.10.3 Teaching and Research Institutions
12.10.4 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Carcinoembryonic Antigen Assay Kit Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Carcinoembryonic Antigen Assay Kit Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Carcinoembryonic Antigen Assay Kit Market Size Forecast by Type
13.6.1 Chemiluminescence Method
13.6.2 Microparticle enzyme-linked Immunoassay
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Carcinoembryonic Antigen Assay Kit Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Pharmacy
13.10.3 Teaching and Research Institutions
13.10.4 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Carcinoembryonic Antigen Assay Kit Market: Competitive Dashboard
14.2 Global Carcinoembryonic Antigen Assay Kit Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Siemens
14.3.2 Abbott Ireland Diagnostics Limited
14.3.3 Roche Diagnostics GmbH
14.3.4 Danaher
14.3.5 Biomatik
14.3.6 RayBiotech, Inc.
14.3.7 LifeSpan BioSciences
14.3.8 Biorbyt
14.3.9 OriGene Technologies
14.3.10 Aviva Systems Biology Corporation
